Drugs / CPC-201
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02434666 | Jan 2015 → Oct 2016 | Alzheimer disease | Chase Pharmaceuticals Corporation, an affiliate of Allergan plc | Completed | No outcome recorded |
| Phase 2 | NCT02185053 | Jul 2014 → Jul 2016 | Alzheimer disease | Chase Pharmaceuticals Corporation, an affiliate of Allergan plc | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CPC-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02185053 ↗ |